When used in combination with existing therapies such as anti-PD-1/PD-L1, IGSF11-VISTA axis inhibition enhances treatment outcomes by boosting inflammation and immune cell infiltration, making it a powerful immune modulator in emerging cancer therapies. The gene discussed is VSIR; the disease is cancer.